European Commission approves the Marketing Authorization for Ripretinib (Qinlock (R)) for the Fourth-line Treatment of gastrointestinal Stromal Tumors

Anonymous

首页> 外文期刊>Oncology research and treatment. >European Commission approves the Marketing Authorization for Ripretinib (Qinlock (R)) for the Fourth-line Treatment of gastrointestinal Stromal Tumors

【24h】

European Commission approves the Marketing Authorization for Ripretinib (Qinlock (R)) for the Fourth-line Treatment of gastrointestinal Stromal Tumors

机译：European Commission approves the Marketing Authorization for Ripretinib (Qinlock (R)) for the Fourth-line Treatment of gastrointestinal Stromal Tumors

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相关主题

著录项

来源
《Oncology research and treatment.》 |2022年第3期|140-140|共1页
作者
Anonymous;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词

客服邮箱：kefu@zhangqiaokeyan.com

客服微信
服务号

European Commission approves the Marketing Authorization for Ripretinib (Qinlock (R)) for the Fourth-line Treatment of gastrointestinal Stromal Tumors

著录项

相关主题

期刊订阅